Published in Cancer Weekly, December 24th, 2002
The NCI's decision to collaborate with Vion was based on a review of existing Triapine preclinical and clinical data. As part of the collaboration, the NCI's Cancer Therapy Evaluation Program will sponsor clinical trials of Triapine to further explore its activity as a single agent or in combination with other agents in patients with cancer. Trials to be sponsored by the NCI will be determined after execution of a clinical trials...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.